RIPK3 and steatosis: The PNPLA3 148M variant promotes MASLD through a macrophage-specific NF-κB–NACC1–RIPK3 axis that enhances necroptosis and inflammatory signaling, thereby exacerbating hepatocyte steatosis and HSC activation.